Patents by Inventor Martin Fleisher

Martin Fleisher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10113200
    Abstract: The invention relates to a method for the Cell Type specific labeling with Amino acid Precursors (CTAP). In particular, the disclosed method permits the incorporation of stable isotope-labeled amino acids into the proteome of a vertebrate cell that has been engineered to express an exogenous enzyme that enables the cell to produce an essential amino acid from its amino acid substrate. The method employs stable isotope-labeled amino acid substrate/precursors from which essential amino acids bearing the label are generated. The labeled amino acids generated by the transgenic cell not only supports growth but specifically labels proteins of the transgenic cell. Furthermore, the use of different populations of cells expressing different exogenous amino acid-producing enzymes permits differential labeling of the proteomes of the individual cell populations in multicellular environments.
    Type: Grant
    Filed: September 16, 2013
    Date of Patent: October 30, 2018
    Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Daniel C. Danila, Howard I. Scher, Martin Fleisher
  • Patent number: 10030271
    Abstract: Using an RT-PCR platform, detection of gene transcripts highly expressed in prostate tissue and expressed in peripheral blood mononuclear cells (PBMC) from patients with mCRPC can provide a more reliable and robust prediction of poor overall survival than that of CTC enumeration in mCRPC. Disclosed is the identification of five genes, KLK3, KLK2, HOXB13, GHRL2 and FOXA1, the detection of two (2) or more transcripts of which predicts overall poor survival. The test is performed on blood samples that have been collected in collection tubes that stabilize intracellular RNA, require minimal on-site processing and can be easily stored and shipped for subsequent extraction of total RNA from whole blood for RT-PCR.
    Type: Grant
    Filed: August 19, 2013
    Date of Patent: July 24, 2018
    Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Howard Scher, Martin Fleisher, Daniel Danila
  • Publication number: 20150240314
    Abstract: The invention relates to a method for the Cell Type specific labeling with Amino acid Precursors (CTAP). In particular, the disclosed method permits the incorporation of stable isotope-labeled amino acids into the proteome of a vertebrate cell that has been engineered to express an exogenous enzyme that enables the cell to produce an essential amino acid from its amino acid substrate. The method employs stable isotope-labeled amino acid substrate/precursors from which essential amino acids bearing the label are generated. The labeled amino acids generated by the transgenic cell not only supports growth but specifically labels proteins of the transgenic cell. Furthermore, the use of different populations of cells expressing different exogenous amino acid-producing enzymes permits differential labeling of the proteomes of the individual cell populations in multicellular environments.
    Type: Application
    Filed: September 16, 2013
    Publication date: August 27, 2015
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Daniel C. Danila, Howard I. Scher, Martin Fleisher
  • Publication number: 20150191792
    Abstract: Using an RT-PCR platform, detection of gene transcripts highly expressed in prostate tissue and expressed in peripheral blood mononuclear cells (PBMC) from patients with mCRPC can provide a more reliable and robust prediction of poor overall survival than that of CTC enumeration in mCRPC. Disclosed is the identification of five genes, KLK3, KLK2, HOXB13, GHRL2 and FOXA1, the detection of two (2) or more transcripts of which predicts overall poor survival. The test is performed on blood samples that have been collected in collection tubes that stabilize intracellular RNA, require minimal on-site processing and can be easily stored and shipped for subsequent extraction of total RNA from whole blood for RT-PCR.
    Type: Application
    Filed: August 19, 2013
    Publication date: July 9, 2015
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Howard Scher, Martin Fleisher, Daniel Danila
  • Patent number: 4695471
    Abstract: A method for screening breast cyst fluid to identify patients having a high risk of developing breast cancer, comprising the steps of measuring the chloride ion content of breast cyst fluid aspirated from the patient; and correlating the chloride ion concentration with the risk of developing breast cancer.
    Type: Grant
    Filed: July 30, 1984
    Date of Patent: September 22, 1987
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Martin Fleisher, H. Leon Bradlow, Morton K. Schwartz
  • Patent number: 4493892
    Abstract: A process and reagent for determining the presence of fecal occult blood in a test sample using a guaiac-peroxidase test matrix and a means for inhibiting peroxidase enzyme interferences which combines the partial denaturing of peroxidase enzyme protein using a protein-hydrogen bond cleaving agent, with the removal of metals necessary for efficient peroxidase enzyme activity wherein the improvement comprises dissolving said reagent for cleaving protein-hydrogen bonds in an alcohol-water solvent before adding said reagent to the sample.
    Type: Grant
    Filed: December 20, 1982
    Date of Patent: January 15, 1985
    Assignee: Memorial Hospital for Cancer & Allied Diseases
    Inventor: Martin Fleisher
  • Patent number: 4492124
    Abstract: A sampling system for stool analysis provides an elongated handle and a cylindrical coring device, said handle including means for releasibly holding said coring device. The coring device is inserted into the stool to collect a representative sample. The sample is removed for analysis, as required.
    Type: Grant
    Filed: July 30, 1982
    Date of Patent: January 8, 1985
    Assignee: Memorial Hospital for Cancer and Allied Diseases
    Inventors: Martin Fleisher, Sidney J. Winawer
  • Patent number: 4333734
    Abstract: Diagnostic test device for fecal occult blood utilizing a test matrix such as paper impregnated with guaiac. False-positive results in the presence of peroxidases are prevented by adding to the matrix a compound that cleaves protein hydrogen bonds such as guanidine hydrochloride and a chelating agent that binds calcium and/or magnesium such as EDTA.
    Type: Grant
    Filed: October 8, 1980
    Date of Patent: June 8, 1982
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventor: Martin Fleisher